

CRYSTALLINE FORM OF COMPOUND, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE

ABSTRACT

The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure are also stable under high temperature, high humidity, oxidizing conditions, and thus advantageous for storage and transportation and for industrial production. In addition, the crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure have higher bioavailability, thus meeting clinical medication requirements.

FIG. 3 accompanies the abstract.